NCT05632393View on ClinicalTrials.gov

A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 16, 2023

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Healthy
Interventions
DRUG

Daridorexant

Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.

Trial Locations (1)

53704

Labcorp Clinical Research Unit Inc., Madison

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT05632393 - A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women | Biotech Hunter | Biotech Hunter